Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty
Status:
Withdrawn
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose
regardless of their pre-operative risk of transfusion. Therefore the aim of the study is to
determine whether or not repeated dosing of oral TXA reduces the post-operative reduction in
hemoglobin, hematocrit, number of transfusions, and post-operative blood loss following
primary TKA and THA surgeries in patients with low pre-operative hematocrit and high risk for
transfusion. The investigators hypothesize that a multi-dose TXA regimen will significantly
minimize post-operative blood loss and transfusion requirements compared to the use of a
single dose regime.